Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elafibranor Mechanistic Study in NAFL
NCT03953456Phase 2Terminated
- Sponsor
- Genfit
- Start
- Aug 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of elafibranor in non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Genfit. Primary endpoint: Change in relative amount of saturated fatty acids in the liver at 6 weeks. Started Aug 2019; status: terminated.
02
Drugs
elafibranor
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03953456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03953456.